HyGro,
If all you were saying was true, and if you truly worked in the industry, if you see the evidence of efficacy in the data and believe that it's possible that DCVax-L and Direct could potentially be a new paradigm in the treatment of solid cancers, would you delay it's approval on the technicalities you believe are flaws in the trial.
I believe the results speak for themselves regardless how they're arrived at. It was really the German's who saw the benefits and got all the regulators to make the change so all entering the trial got DCVax-L, frankly if the regulators really wanted to act dynamically, they would have approved the vaccine then, but production would have been by clean room methodology for years while the FlaskWorks unit was being upgraded and approved and mass produced.
You tell me, would you not approve the vaccine knowing it was saving lives because of your belief that the trial should have been done differently.
Gary
Market Data 
Markets 
AI
